Login / Signup

Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy).

Giacomo PontaValentina MorenaMartina StranoChiara MolteniSilvia PontiggiaErica Michela CavalliAnna GranciniCarola MauriAntonella CastagnaAndrea GalantiStefania Piconi
Published in: Antimicrobial agents and chemotherapy (2024)
Rezafungin is an echinocandin characterized by a long elimination half-life which allows for weekly administration. It has been recently approved for the treatment of candidemia. Few data are available about the long-term use of rezafungin and its use for deep infections like endocarditis and osteomyelitis. We describe our experience with its prolonged use in two azole-resistant Candida infections: a case of sacral osteomyelitis and a prosthetic valve endocarditis also involving a thoracic endovascular aneurysm repair.
Keyphrases
  • healthcare
  • candida albicans
  • emergency department
  • mitral valve
  • staphylococcus aureus
  • cystic fibrosis
  • electronic health record
  • atrial fibrillation
  • big data
  • left ventricular
  • adverse drug
  • acute care